Latest News - AbbVie

Friday, October 27, 2017 | Phase 3/4 Trials,, Research and Publications, AbbVie

Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent imp…

Read the full story

Tuesday, August 29, 2017 | Corporate Lawsuits, FDA Approval/Clearance,, AbbVie, Boehringer Ingelheim, Psoriasis

FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseases

The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multip…

Read the full story

Thursday, July 27, 2017 |, Product Launches and Updates, AbbVie, Boehringer Ingelheim

Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humira

The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 4…

Read the full story

Thursday, March 30, 2017 | FDA Approval/Clearance,, Product Launches and Updates, AbbVie

FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Information

The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis…

Read the full story

Tuesday, May 03, 2016 |,,, Research and Publications, AbbVie, Johnson & Johnson

Global Derm Market Set to Soar Through 2022

The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%, GBI Research reports. This rise will occur despit…

Read the full story

Wednesday, April 13, 2016 | Business of Medicine,, AbbVie, Amgen, Johnson & Johnson, Psoriasis

Psoriasis Market Poised for Growth Spurt by 2024

The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a new report from GlobalData. The market will rise from $6.6 billion in 2014 to over …

Read the full story

Thursday, September 10, 2015 | FDA Approval/Clearance, AbbVie

FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativa

The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults wi…

Read the full story

Friday, May 15, 2015 | FDA Approval/Clearance, Product Launches and Updates, AbbVie

AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa

AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hu…

Read the full story